General Information of Drug (ID: DM6OUW0)

Drug Name
(S)-2-amino-3-(benzylthio)propanoic acid Drug Info
Synonyms
H-D-Cys(Bzl)-OH; 23032-53-3; S-benzyl-D-cysteine; (S)-Benzyl-D-Cys; CHEMBL204162; CCRIS 1971; Alanine, 3-(benzylthio)-, L-; EINECS 221-273-4; (S)-2-AMINO-3-(S-BENZYLTHIO)PROPANOIC ACID; AC1Q5R1B; AC1L2QY5; SCHEMBL1927561; D-Cysteine, S-(phenylmethyl)-; CTK7D0951; MolPort-005-937-279; GHBAYRBVXCRIHT-SECBINFHSA-N; ZINC404299; BDBM50179697; AS-49045; AJ-22311; AX8012175; LS-188299
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
76454
TTD Drug ID
DM6OUW0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diltiazem DMAI7ZV Angina pectoris BA40 Approved [2]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [3]
Lercanidipine DMPWSEM Hypertension BA00-BA04 Approved [4]
Pregabalin DMDVP3B Chronic obstructive pulmonary disease CA22 Approved [5]
Amlodipine DMBDAZV Angina pectoris BA40 Approved [6]
Mirogabalin DM5GIWZ Peripheral neuropathy 8C0Z Registered [7]
Imagabalin DMRLVUD Generalized anxiety disorder 6B00 Phase 3 [8]
NP-118809 DM8A64W Pain MG30-MG3Z Discontinued in Phase 2 [9]
PD-144550 DM03526 Discovery agent N.A. Investigative [10]
3-Aminomethyl-5-methyl-hexanoic acid DMTYXH1 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) TTFK1JQ CA2D1_HUMAN Inhibitor [1]

References

1 Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41.
2 Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24.
3 Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80.
4 Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7.
5 Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76.
6 A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94.
7 Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61.
8 Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9.
9 Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72.
10 Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994).